0 (65.six) 18 (14.8) 30 (24.6) 6 (4.9) 34 (28.1) BAV-LN n = 11 (2 ) 46.6 17.1 5 (45.five) 2 (18.two) three (27.three) 0 (0) two (18.2) p ValueDemographics and 3-Chloro-5-hydroxybenzoic acid web clinical data Age, years Male, n
0 (65.six) 18 (14.eight) 30 (24.six) 6 (four.9) 34 (28.1) BAV-LN n = 11 (two ) 46.six 17.1 5 (45.five) two (18.2) three (27.three) 0 (0) 2 (18.2) p ValueDemographics and clinical data Age, years Male, n Smoking, n Hypertension, n Diabetes mellitus, n Dyslipidemia, n 0.039 0.125 0.023 0.670 0.911 0.J. Clin. Med. 2021, 10,4 ofTable 1. Cont. Variable All Patients n = 718 BAV-RL n = 585 (81 ) BAV-RN n = 122 (17 ) BAV-LN n = 11 (2 ) p ValueValve abnormality and dysfunction Raphe, n Calcification mild, n Normofuntional 637 (88.7) 57 (7.9) 341 (47.five ) 524 (89.6) 48 (8.2) 282 48.2 ) 102 (83.6) 8 (six.6) 58 (47.five ) 11 (one hundred) 1 (9.1) 1 (9.0 ) 0.four of 11 J. Clin. Med. 2021, 10, x FOR PEER REVIEW0.421 0.200 (27.9) 167 30 (24.six) three (27.3) 0.670 AS, n 19 (15.six) (28.six) 3 (27.3) 0.566 40 (5.six) 34 (5.eight) 6 (4.9) 0 (0) 0.911 AR, n 45 7 (28.1) 196 (27.3) (36.9) (27.4) 160 34 (63.6) 2 (18.two) 0.184 0.867 Valve abnormality Aortic diameter, dilation and morphotype and dysfunction Raphe, n 637 (88.7) 524 (89.6) 102 (83.6) 11 (100) 0.096 Aortic root, mm 36.three five.4 Calcification mild,n 36.9 5.four 33.9 4.two 32.9 7.1 0.001 57 (7.9) 48 (8.2) eight (six.6) 1 (9.1) 0.421 Ascending aorta, mm 39.2 6.2 39.two 6.three 39.0 five.7 40.7 6.6 0.812 Normofuntional 341 (47.five ) 282 48.two ) 58 (47.five ) 1 (9.0 ) 0.623 Sinusal Z score 1.three 1.four 1.four 1.four 0.8 1.three 0.5 1.9 0.001 AS, n 116 (16.2) 94 (16.1) 19 (15.6) three (27.three) 0.566 Ascending aorta Z score two.eight 1.5 2.9 3.five(36.9) AR,two.7 1.five n 261(36.4) 1.five (35.7) 209 45 1.7 7 (63.six) 0.176 0.184 Aortic diameter, dilation and morphotype Non-dilated aorta 181 (25.two) 148 (25.3) 31 (25.four) two (18.two) 0.953 Aortic root, mm 36.3 five.4 36.9 5.four 33.9 4.two 32.9 7.1 0.001 Aortic root morphotype 86 (12.0) Ascending aorta, mm 84 (14.4) two 0 (0) 39.2 six.two (1.six) 39.two six.3 39.0 five.7 40.7 6.6 0.001 0.812 Sinusal Z score 1.3 1.4 (72.9) 1.four 1.four Tubular morphotype 451 (62.8) 353 (60.3) 89 90.8 1.three (81.eight) 0.5 1.9 0.001 0.02 Ascending aorta Z score 2.eight 1.5 2.7 1.5 2.9 1.five 3.5 1.7 0.176 p 0.001; p 0.05. AS: Aortic stenosis AR: Aortic regurgitation NS: not significant. Non-dilated aorta 181 (25.2) 148 (25.three) 31 (25.four) two (18.2) 0.953 Aortic root morphotype 86 (12.0) 84 (14.four) two (1.six) 0 (0) 0.001 In the baseline study, no or mild valvular dysfunction was JPH203 Biological Activity present in 403 (56.1 ) Tubular morphotype 451 (62.8) 353 (60.three) 89 (72.9) 9 (81.8) 0.116 (16.two) Hypertension, n 94 (16.1) Diabetes mellitus, n 261(36.four) 209 (35.7) Dyslipidemia, n patients, moderate valvular AS: Aortic stenosis AR: Aortic regurgitation NS: not important. p 0.001; p 0.05. stenosis in 116 (16.two ) and moderate regurgitation in 199 (27.7 ). More-than-mild aortic calcification was present in 57 people (7.9 ). Aortic In have been extra frequently dysfunctional, with significant 403 (56.1 ) valves with raphe the baseline study, no or mild valvular dysfunction was present in aortic stenosis sufferers, moderate valvular stenosis in 116 (16.2 ) and moderate regurgitation in 199 in 18.two vs. 0 (p 0.001), considerable regurgitation in 38.9 vs. 16.1 (p 0.001) and (27.7 ). More-than-mild aortic calcification was present in 57 individuals (7.9 ). Aortic calcification in 8.9 vs. 0 (p 0.001). valves with raphe had been more often dysfunctional, with significant aortic stenosis in three.two. Aorta Dilation and Valvular Dysfunction Progression calcification in 8.9 vs. 0 (p 0.001).18.two vs. 0 (p 0.001), significant regurgitation in 38.9 vs. 16.1 (p 0.001) andAfter a imply follow-up of 7.2 years [IQR 5] (variety 55 years), aortic root diameters 3.2. Aorta Dilation and Valvular Dysfunction Progress.
